Leerink Partnrs Has Pessimistic Outlook of REGN Q1 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Analysts at Leerink Partnrs decreased their Q1 2025 earnings estimates for shares of Regeneron Pharmaceuticals in a research note issued on Tuesday, April 1st. Leerink Partnrs analyst D. Risinger now forecasts that the biopharmaceutical company will post earnings of $7.07 per share for the quarter, down from their previous forecast of $7.56. Leerink Partnrs currently has a “Strong-Buy” rating on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ Q2 2025 earnings at $8.22 EPS, Q3 2025 earnings at $9.62 EPS, Q4 2025 earnings at $9.56 EPS, FY2025 earnings at $34.47 EPS and FY2026 earnings at $35.16 EPS.

REGN has been the subject of several other reports. JPMorgan Chase & Co. decreased their price objective on shares of Regeneron Pharmaceuticals from $1,100.00 to $1,000.00 and set an “overweight” rating for the company in a research report on Monday, March 31st. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a report on Monday, January 27th. Leerink Partners raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their price objective for the company from $762.00 to $834.00 in a report on Wednesday, February 5th. Bernstein Bank reduced their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Finally, TD Cowen lowered their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating for the company in a research report on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $966.88.

Regeneron Pharmaceuticals Trading Down 6.1 %

Regeneron Pharmaceuticals stock opened at $573.45 on Thursday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The stock has a market cap of $62.69 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The stock has a 50-day moving average of $676.70 and a two-hundred day moving average of $781.68. Regeneron Pharmaceuticals has a one year low of $572.00 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s quarterly revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the firm posted $11.86 earnings per share.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Several hedge funds have recently modified their holdings of the company. Pinney & Scofield Inc. acquired a new position in Regeneron Pharmaceuticals in the 4th quarter worth about $25,000. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 15 shares in the last quarter. OFI Invest Asset Management acquired a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $28,000. Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals during the 4th quarter valued at approximately $36,000. Finally, Crowley Wealth Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at $36,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.61%. Regeneron Pharmaceuticals’s payout ratio is 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.